What\'s knownThe clinical and economic burdens of smoking have been demonstrated in various geographies, particularly in the US and EU, with the cost attributed to smoking reaching in the billions of dollars annually. Additionally, work productivity has been shown to suffer for those who are smoking. Despite the health benefits resulting from smoking cessation, many employers do not support smoking cessation programs.What\'s newThis study examines the impact of smoking on work productivity in multiple geographies using the same methodology: US, EU and China. Additionally, the time to improvement in workplace productivity following cessation is investigated. This study provides evidence that those who have quit smoking have substantially greater work productivity in examined geographies.

1. Introduction {#ijcp12900-sec-0008}
===============

Smoking and tobacco use exert a tremendous global health and economic burden. As of 2015, direct tobacco use is associated with over 5 million deaths annually among the estimated 1 billion smokers worldwide, as well as an additional over 600,000 deaths caused by exposure to second‐hand smoke.[1](#ijcp12900-bib-0001){ref-type="ref"} The use of tobacco products is associated with increased risk of some of the leading global causes of mortality, including heart disease, cancer, respiratory diseases, and cerebrovascular disease.[2](#ijcp12900-bib-0002){ref-type="ref"}

Approximately 21% of the global adult population are current smokers.[3](#ijcp12900-bib-0003){ref-type="ref"} Smoking prevalence is dependent, in part, on societal acceptance of smoking, with lower prevalence in areas with greater public policy efforts \[eg, 16.8% of adults in the United States (US), 19.2% in Great Britain, 19.5% in Italy\] and higher prevalence in areas without strong policy environments (eg, 34.1% in France, 27% in Spain, 24.5% in Germany, 27.7% in China).[3](#ijcp12900-bib-0003){ref-type="ref"}, [4](#ijcp12900-bib-0004){ref-type="ref"} Smoking also causes significant societal consequences globally in the form of work productivity impairment. Working smokers in the US are estimated to miss an average of 2.3 more workdays annually than those who have never smoked and be less productive while at work.[5](#ijcp12900-bib-0005){ref-type="ref"}, [6](#ijcp12900-bib-0006){ref-type="ref"}, [7](#ijcp12900-bib-0007){ref-type="ref"}

In addition to health and work‐related impairment, smoking is also associated with substantial direct and indirect costs. The estimated cost attributable to the burden of smoking is between \$289 and \$333 billion annually in the US alone.[2](#ijcp12900-bib-0002){ref-type="ref"} These costs are because of both medical care for smoking‐related illnesses and the substantial work‐related loss attributable to early mortality.[2](#ijcp12900-bib-0002){ref-type="ref"} Further costs for non‐smokers have been reported at an estimated \$6 billion in productivity loss caused by second‐hand exposure; however, this is much lower than the substantially higher estimates of \$151 billion for smokers.[2](#ijcp12900-bib-0002){ref-type="ref"}

Further studies outside the US have reported similar findings regarding work loss and associated costs. An EU study of over 10 000 workers in the Netherlands found that smoking status was associated with an increased use of sick leave and lost productivity while at work.[8](#ijcp12900-bib-0008){ref-type="ref"} Similarly, two German‐based studies have reported significant costs as a result of smoking‐related productivity loss,[9](#ijcp12900-bib-0009){ref-type="ref"} including one in which annual productivity costs as a result of smoking were estimated to be in excess of €9.6 billion.[10](#ijcp12900-bib-0010){ref-type="ref"} Finally, in China, smoking was associated with significantly higher rates of presenteeism in a cross‐sectional survey of workers at one large corporation.[11](#ijcp12900-bib-0011){ref-type="ref"} These authors concluded that health‐promoting programs should be made available to all workers to limit the impact of smoking and other risk factors for poor health and impaired work productivity.

Importantly, evidence suggests that a number of benefits are associated with smoking cessation, with the risk of cancer and heart disease reduced after approximately 12 months of non‐smoking.[12](#ijcp12900-bib-0012){ref-type="ref"} Quitting smoking has also been found to drastically reduce direct and indirect costs, which can benefit payers, employers, employees and society as a whole.[13](#ijcp12900-bib-0013){ref-type="ref"} Those who have quit smoking not only save money from no longer purchasing cigarettes but may also gain from reduced health and life insurance expenses, as well as lower healthcare costs caused by smoking‐related illnesses.[14](#ijcp12900-bib-0014){ref-type="ref"}

The increase in work productivity when smokers quit has led some employers to invest in smoking cessation programs, often including pharmacotherapy and behavioural interventions.[5](#ijcp12900-bib-0005){ref-type="ref"}, [15](#ijcp12900-bib-0015){ref-type="ref"}, [16](#ijcp12900-bib-0016){ref-type="ref"} Although a cost exists for employers to implement smoking cessation programs, employers still save money per employee who quits smoking when the indirect savings from smoking cessation are considered, thus making it both health conscious and cost‐effective to implement such programs.[16](#ijcp12900-bib-0016){ref-type="ref"}, [17](#ijcp12900-bib-0017){ref-type="ref"} Despite such positive findings, however, many employers globally fail to cover quit programs in the workplace[18](#ijcp12900-bib-0018){ref-type="ref"} and smoking rates continue to rise in many regions.[20](#ijcp12900-bib-0020){ref-type="ref"}

In order to demonstrate the tangible value to employers and society as a whole of successful smoking cessation in the employee population, it is important to investigate the effect of years since quitting and the impact of smoking on workplace productivity. As a result, this study seeks to expand the understanding of the work‐related burden associated with smoking and quitting across the US, the European Union (EU), and China using large‐scale representative survey methodology.

2. Materials and methods {#ijcp12900-sec-0009}
========================

2.1. Sample {#ijcp12900-sec-0010}
-----------

This analysis includes data from the 2013 National Health and Wellness Survey (NHWS) from the US (N=75 000), EU5 (N=62 000; including UK, France, Germany, Italy and Spain), and China (N=19 987). The NHWS is a self‐administered, Internet‐based questionnaire from a sample of adults aged 18 or older.

A stratified random sample (with strata by gender and age in EU5 and China, and race/ethnicity added in the US) was implemented to ensure that the demographic composition is representative of the corresponding adult population based on: data from the International Data Base of the US Census Bureau for the EU and China, and data from the US Census for the US. For regions outside the US, online recruitment was supplemented by offline recruitment to reach elderly people who may not have Internet access. Several peer‐reviewed publications have previously favourably compared the NHWS with other governmental sources.[20](#ijcp12900-bib-0020){ref-type="ref"}, [21](#ijcp12900-bib-0021){ref-type="ref"}, [22](#ijcp12900-bib-0022){ref-type="ref"} The NHWS sample for the current study includes only working‐age respondents aged 18‐64: 2013 US NHWS (N=58 500), 2013 EU5 NHWS (N=50 417), and 2013 China NHWS (N=17 987).

2.2. Measures {#ijcp12900-sec-0011}
-------------

### 2.2.1. Independent variables: smoking status and years since quit {#ijcp12900-sec-0012}

Respondents were broken into four groups based on self‐reported smoking behaviour in each region: current smoker (those currently smoking), those trying to quit (those in the process of quitting or using cessation products), former smokers (those who previously but no longer smoke), and never smokers (those who have never smoked).

Additional analyses compared current smokers to former smokers by further examining how years since quitting smoking, 0‐4 years ago, 5‐10 years ago and 11 or more years ago, was related to outcomes.

### 2.2.2. Demographics and health characteristic variables {#ijcp12900-sec-0013}

The following demographic and health characteristic variables were examined for differences between groups: age, sex, race/ethnicity (for US only) and education. The following health characteristics were also examined: body mass index (BMI) category and comorbidity burden \[measured via the Charlson Comorbidity Index (CCI)[23](#ijcp12900-bib-0023){ref-type="ref"}\].

### 2.2.3. Outcome variables {#ijcp12900-sec-0014}

Work productivity loss and activity impairment were measured via the validated Work Productivity and Activity Impairment‐General Health questionnaire (WPAI‐GH; <http://www.reillyassociates.net/WPAI>\_GH.html[24](#ijcp12900-bib-0024){ref-type="ref"}), included in the NHWS. The WPAI measures four constructs: absenteeism (the percentage of work time missed because of one\'s health problems in the past 7 days), presenteeism (the percentage of impairment experienced while at work in the past 7 days because of one\'s health problems), overall impairment (an overall impairment estimate that is a combination of absenteeism and presenteeism) and activity impairment (the percentage of impairment in daily activities because of one\'s health problems in the past 7 days). Only respondents who reported being full‐time or part‐time employed (via the labour force participation question) provided data for absenteeism, presenteeism and overall work impairment. All respondents provided data for activity impairment.

2.3. Analyses {#ijcp12900-sec-0015}
-------------

All analyses were conducted using [spss]{.smallcaps} version 20, Armonk, NY, USA. Demographic and health characteristic differences were examined by smoking status. For categorical variables, chi‐square tests were used to determine significant differences while one‐way analyses of variance (ANOVAs) were used for continuous variables when comparing the smoking groups. Frequencies (N) and percentages (%) are reported for categorical variables and means, and standard deviations are reported for continuous variables.

Two‐sided *P*‐value, *P*\<.05, indicated statistical significance. To account for multiple comparisons,[25](#ijcp12900-bib-0025){ref-type="ref"} a Bonferroni correction was implemented such that the critical *P*‐value (*P*\<.05) was divided by number of comparisons (eg, five) to yield a new critical *P*‐value, *P*\<.01.

Following initial comparisons, generalised linear models were used to assess benefits of smoking cessation on work productivity and activity impairment after controlling for covariates. Covariates included: age, sex, race/ethnicity (in US only), education, BMI category and CCI. Estimated means, standard errors, and 95% confidence intervals are reported. Two‐sided *P*‐value, *P*\<.01, indicated statistical significance for pairwise comparisons assessing smoking status (ie, five comparisons) and a *P*\<.017 indicated statistical significance for pairwise comparisons assessing years since quit (ie, three comparisons).[24](#ijcp12900-bib-0024){ref-type="ref"}

3. Results {#ijcp12900-sec-0016}
==========

3.1. Initial group comparisons {#ijcp12900-sec-0017}
------------------------------

The percentages of current smokers were 13.4% in the US, 15.6% in China and 21.2% in EU5 (see Table [1](#ijcp12900-tbl-0001){ref-type="table-wrap"} for smoking group sample sizes for all three regions). Analyses examining demographic and health characteristics demonstrated that there were significant differences for each of these variables across smoking groups for US, EU5 and China (*P*\<.001 for all; see Tables [2](#ijcp12900-tbl-0002){ref-type="table-wrap"}, [3](#ijcp12900-tbl-0003){ref-type="table-wrap"}, [4](#ijcp12900-tbl-0004){ref-type="table-wrap"}). These variables were retained as covariates in the multivariable analyses.

###### 

Sample sizes for each region for according to smoking status

          Current smoker   Trying to quit   Former smoker   Never smoker    Total
  ------- ---------------- ---------------- --------------- --------------- --------
  US      7813 (13.4)      4121 (7.0)       13 445 (23.0)   33 121 (56.6)   58 500
  EU5     10 713 (21.2)    3710 (7.4)       13 647 (27.1)   22 347 (44.3)   50 417
  China   2804 (15.6)      1584 (8.8)       2208 (12.3)     11 391 (63.3)   17 987

Values within parenthesis are expressed as percentage.

EU5=UK, Germany, Italy, France and Spain.
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###### 

Demographics and health characteristics by smoking status for US

        Smoking status                                                                           
  ----- ---------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  Age   43.26            12.18   41.46   12.65   44.68   13.20   40.68   12.84   42.00   12.93   \<.001
  CCI   0.49             1.24    0.59    1.33    0.45    1.05    0.24    0.78    0.35    0.97    \<.001

                                 N      \%     N      \%     N      \%     N       \%     N       \%     
  ------------------------------ ------ ------ ------ ------ ------ ------ ------- ------ ------- ------ --------
  Sex                                                                                                    
  Female                         3639   46.6   2004   48.6   6837   50.9   19279   58.2   31759   54.3   \<.001
  Male                           4174   53.4   2117   51.4   6608   49.1   13842   41.8   26741   45.7   
  Ethnicity                                                                                              
  Non‐Hispanic White             5607   71.8   2651   64.3   9697   72.1   21156   63.9   39111   66.9   \<.001
  Non‐Hispanic Black             885    11.3   622    15.1   1323   9.8    4897    14.8   7727    13.2   
  Hispanic                       716    9.2    455    11.0   1350   10.0   3324    10.0   5845    10.0   
  Other ethnicity                605    7.7    393    9.5    1075   8.0    3744    11.3   5817    9.9    
  Education                                                                                              
  Less than 4‐year degree        6151   78.7   3016   73.2   8661   64.4   16613   50.2   34441   58.9   \<.001
  4‐year degree or more          1662   21.3   1105   26.8   4784   35.6   16508   49.8   24059   41.1   
  BMI category                                                                                           
  Underweight (\<18.5)           244    3.1    103    2.5    187    1.4    841     2.5    1375    2.4    \<.001
  Normal weight (18.5 to \<25)   2829   36.2   1416   34.4   3746   27.9   11876   35.9   19867   34.0   
  Overweight (25 to \<30)        2418   30.9   1334   32.4   4228   31.4   9562    28.9   17542   30.0   
  Obese (≥30)                    2189   28.0   1203   29.2   4979   37.0   9700    29.3   18071   30.9   
  Unknown                        133    1.7    65     1.6    305    2.3    1142    3.4    1645    2.8    

SD, standard deviation; CCI, Charlson Comorbidity Index; BMI, body mass index. *P*‐values represent the omnibus comparisons noting significant differences across the smoking groups and are derived from one‐way ANOVAs (for continuous measures) or chi‐squared tests (for categorical measures) and are two‐sided.
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###### 

Demographics and health characteristics by smoking status for EU5

        Smoking Status   *P*‐value                                                                   
  ----- ---------------- ----------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  Age   41.81            11.77       41.17   12.19   44.25   12.66   39.81   12.40   41.54   12.46   \<.001
  CCI   0.33             0.98        0.45    1.29    0.31    0.80    0.18    0.62    0.26    0.82    \<.001

                                 N      \%     N      \%     N      \%     N       \%     N       \%     
  ------------------------------ ------ ------ ------ ------ ------ ------ ------- ------ ------- ------ --------
  Sex                                                                                                    
  Female                         5950   55.5   1883   50.8   7426   54.4   12986   58.1   28245   56.0   \<.001
  Male                           4763   44.5   1827   49.2   6221   45.6   9361    41.9   22172   44.0   
  Education                                                                                              
  Less than university           7298   68.1   2264   61.0   8233   60.3   12137   54.3   29932   59.4   \<.001
  University degree or more      3415   31.9   1446   39.0   5414   39.7   10210   45.7   20485   40.6   
  BMI category                                                                                           
  Underweight (\<18.5)           447    4.2    128    3.5    332    2.4    837     3.7    1744    3.5    \<.001
  Normal weight (18.5 to \<25)   5241   48.9   1766   47.6   5628   41.2   10809   48.4   23444   46.5   
  Overweight (25 to \<30)        3112   29.0   1137   30.6   4467   32.7   6401    28.6   15117   30.0   
  Obese (≥30)                    1670   15.6   605    16.3   2871   21.0   3383    15.1   8529    16.9   
  Unknown                        243    2.3    74     2.0    349    2.6    917     4.1    1583    3.1    

SD, standard deviation; CCI, Charlson Comorbidity Index; BMI, body mass index. *P*‐values represent the omnibus comparisons noting significant differences across the smoking groups and are derived from one‐way ANOVAs (for continuous measures) or chi‐squared tests (for categorical measures) and are two‐sided.
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###### 

Demographics and health characteristics by smoking status for China

        Smoking Status                                                                           
  ----- ---------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  Age   39.54            11.07   37.32   11.01   36.76   11.37   38.54   11.96   38.37   11.70   \<.001
  CCI   0.35             1.06    0.53    1.36    0.27    0.75    0.19    0.56    0.25    0.79    \<.001

                                 N      \%     N      \%     N      \%     N      \%     N       \%     
  ------------------------------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ------ --------
  Sex                                                                                                   
  Female                         243    8.7    212    13.4   398    18.0   6106   53.6   6959    38.7   \<.001
  Male                           2561   91.3   1372   86.6   1810   82.0   5285   46.4   11028   61.3   
  Education                                                                                             
  College or lower               1117   39.8   499    31.5   758    34.3   4148   36.4   6522    36.3   \<.001
  University or over             1687   60.2   1085   68.5   1450   65.7   7243   63.6   11465   63.7   
  BMI category                                                                                          
  Underweight (\<18.5)           126    4.5    67     4.2    140    6.3    947    8.3    1280    7.1    \<.001
  Normal weight (18.5 to \<25)   1736   61.9   1026   64.8   1459   66.1   7781   68.3   12002   66.7   
  Overweight (25 to \<30)        634    22.6   361    22.8   446    20.2   1749   15.4   3190    17.7   
  Obese (≥30)                    279    10.0   120    7.6    146    6.6    777    6.8    1322    7.3    
  Unknown                        29     1.0    10     .6     17     .8     137    1.2    193     1.1    

SD, standard deviation; CCI, Charlson Comorbidity Index; BMI, body mass index. *P*‐values represent the omnibus comparisons noting significant differences across the smoking groups and are derived from one‐way ANOVAs (for continuous measures) or chi‐squared tests (for categorical measures) and are two‐sided.
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3.2. Multivariable analyses {#ijcp12900-sec-0018}
---------------------------

### 3.2.1. Smoking status {#ijcp12900-sec-0019}

To examine the unique burden of smoking status on work productivity, current smokers and former smokers were compared with each other and were each also compared with those trying to quit and never smokers while controlling for covariates. Covariates included age, gender, race/ethnicity (for US respondents only), education, BMI category and CCI.

In the US, EU5, and China, the workplace burden associated with smoking was clear (see Table [5](#ijcp12900-tbl-0005){ref-type="table-wrap"} for means, standard errors and 95% confidence intervals). Those currently smoking had greater mean presenteeism, overall work impairment and activity impairment than former smokers and never smokers across all three regions (*P*\<.01 for all). Current smokers also had greater absenteeism compared with former and never smokers in US and China and greater absenteeism compared with former smokers in EU5 (*P*\<.01 for all). To illustrate the magnitude of differences, US current smokers had 28% more absenteeism, 28% more presenteeism, 24% more overall work impairment, and 22% more activity impairment than former smokers. In EU5, current smokers had 18% more absenteeism, 18% more presenteeism, 15% more overall work impairment and 12% more activity impairment than former smokers. In China, current smokers had 61% more absenteeism, 16% more presenteeism, 17% more overall work impairment and 13% more activity impairment than former smokers.

###### 

Adjusted means examining effect of smoking status on WPAI‐GH after controlling for demographic and health characteristics[a](#ijcp12900-note-0006){ref-type="fn"}

                                                                      Current smoker (A)   Trying to quit (B)   Former smoker (C)   Never smoker (D)                                                                                                                
  ------------------------------------------------------------------- -------------------- -------------------- ------------------- ------------------ -------- -------- ------- ------ ------------- ------- ------ ------------- -------- -------- ------- ------ -------------
  US                                                                                                                                                                                                                                                                
  Absenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}               4.06                 0.27                 3.57‐4.61           .02                .003     \<.001   5.24    0.47   4.40‐6.24     3.18    0.16   2.88‐3.50     \<.001   .121     2.90    0.09   2.73‐3.08
  Presenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}              16.78                0.43                 15.95‐17.66         .006               \<.001   \<.001   18.89   0.66   17.63‐20.24   13.16   0.25   12.67‐15.73   \<.001   \<.001   12.15   0.14   11.87‐12.43
  Overall work Impairment %[b](#ijcp12900-note-0006){ref-type="fn"}   18.82                0.48                 17.91‐19.78         .003               \<.001   \<.001   21.40   0.74   20.00‐22.90   15.16   0.29   14.60‐13.67   \<.001   \<.001   13.94   0.16   13.63‐14.26
  Activity impairment %                                               25.47                0.39                 24.71‐26.25         .010               \<.001   \<.001   27.23   0.57   26.13‐28.38   20.84   0.25   20.36‐21.32   \<.001   \<.001   18.87   0.14   18.60‐19.15
  EU5                                                                                                                                                                                                                                                               
  Absenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}               5.68                 0.24                 5.23‐6.16           \<.001             .003     .035     7.56    0.55   6.56‐8.72     4.80    0.18   4.46‐5.18     \<.001   .219     5.10    0.15   4.81‐5.40
  Presenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}              17.58                0.30                 17.00‐18.19         \<.001             \<.001   \<.001   21.17   0.64   19.96‐22.45   14.95   0.24   14.49‐15.42   \<.001   .003     15.86   0.19   15.49‐16.24
  Overall work impairment %[b](#ijcp12900-note-0006){ref-type="fn"}   20.97                0.35                 20.29‐21.67         \<.001             \<.001   \<.001   25.49   0.74   24.07‐26.99   18.27   0.28   17.72‐18.83   \<.001   .017     19.14   0.23   18.70‐19.59
  Activity impairment %                                               24.91                0.29                 24.34‐25.49         \<.001             \<.001   \<.001   28.51   0.57   27.42‐29.64   22.23   0.23   21.78‐22.69   \<.001   .824     22.16   0.18   21.81‐22.52
  China                                                                                                                                                                                                                                                             
  Absenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}               8.35                 0.38                 7.64‐9.12           .001               \<.001   \<.001   10.62   0.63   9.45‐11.92    5.20    0.27   4.71‐5.76     \<.001   .991     5.21    0.12   4.97‐5.46
  Presenteeism %[b](#ijcp12900-note-0006){ref-type="fn"}              26.93                0.54                 25.89‐28.02         \<.001             \<.001   \<.001   32.92   0.86   31.29‐34.65   23.20   0.53   22.19‐24.25   \<.001   .859     23.30   0.25   22.83‐23.79
  Overall work impairment %[b](#ijcp12900-note-0006){ref-type="fn"}   30.88                0.61                 29.71‐32.09         \<.001             \<.001   \<.001   37.95   0.97   36.09‐39.91   26.30   0.58   25.18‐27.46   \<.001   .733     26.07   0.27   25.56‐26.60
  Activity impairment %                                               27.06                0.50                 26.09‐28.06         \<.001             \<.001   \<.001   32.77   0.79   31.25‐34.36   23.87   0.49   22.92‐24.85   \<.001   .847     23.97   0.22   23.54‐24.41

SE, standard error; CI, confidence interval. ^a^Covariates included: age, ethnicity (for US only), education, BMI category and CCI. ^b^Asked only of the employed population. For US: Yes, I smoke (N=4382), Trying to quit (N=2329), No, I quit (N=7900), and Never smoked (N=20 713). For EU5: Yes, I smoke (N=7230), Trying to quit (N=2414), No, I quit (N=8665) and Never smoked (N=14 850). For China: Yes, I smoke (N=2488), Trying to quit (N=1423), No, I quit (N=1904) and Never smoked (N=9238).
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In contrast, across all three regions, current smokers had lower impairment on all WPAI‐GH variables than individuals trying to quit (*P*\<.01 for all), except for absenteeism and activity impairment in US. Similarly, former smokers had lower absenteeism, presenteeism, overall work impairment and activity impairment than those trying to quit across all three regions (*P*\<.001 for all).

The pattern is less clear when comparing former smokers to never smokers. In the US, former smokers had greater presenteeism, overall work impairment, and activity impairment than never smokers (*P*\<.001 for all); however, there was no statistically significant difference between former smokers and never smokers on absenteeism. For EU5, former smokers had lower presenteeism than never smokers (*P*\<.01), but there were no statistically significant differences between former smokers and never smokers on absenteeism, overall work impairment and activity impairment. In China, there were no statistically significant differences between former smokers and never smokers on absenteeism, presenteeism, overall work impairment or activity impairment.

### 3.2.2. Years since quit {#ijcp12900-sec-0020}

Follow‐up analyses examined the unique burden of current smokers compared with those who quit while controlling for covariates. Covariates included age, gender, race/ethnicity (for US subjects only), education, BMI category and CCI. Those who have not quit smoking were compared with those who quit within the last 0‐4 years, 5‐10 years and 11 or more years.

Those who quit smoking 0‐4 years ago had lower presenteeism and activity impairment across the US, EU5 and China, and lower overall work impairment in the US and EU5, than current smokers (*P*\<.017 for all). The reduction in impairment resulting from quitting smoking ranged from 7%‐19% for presenteeism, 9%‐16% for overall work impairment and 6%‐13% for activity impairment. For China, those who quit 0‐4 years ago also had lower absenteeism than those still smoking (*P*\<.001); there was a 22% reduction in absenteeism when comparing current smokers to those who quit 0‐4 years ago in China. When comparing those who have not quit to those who quit 5‐10 years ago, current smokers had greater presenteeism, overall work impairment, and activity impairment in all three regions and greater absenteeism in US and China (*P*\<.001 for all). Lastly, current smokers had greater absenteeism, presenteeism, overall work impairment and activity impairment than those who quit 11+ years ago in all three regions (*P*\<.001 for all; see Table [6](#ijcp12900-tbl-0006){ref-type="table-wrap"} for means, standard errors and 95% confidence intervals).

###### 

Adjusted means examining effect of years since quitting on WPAI‐GH after controlling for demographic and health characteristics[a](#ijcp12900-note-0007){ref-type="fn"}

                                                                              Have not quit (A)   0‐4 years (B)   5‐10 years (C)   11+ years (D)                                                                                      
  ------------------------------------------------------------------- ------- ------------------- --------------- ---------------- --------------- --------- ------- ------ ------------- ------- ------ ------------- ------- ------ -------------
  US                                                                                                                                                                                                                                  
  Absenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}               4.61    0.23                4.17‐5.09       .040             \<.001          \<.001    3.82    0.29   3.3‐4.44      3.00    0.28   2.5‐3.6       3.11    0.22   2.71‐3.56
  Presenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}              17.67   0.35                17‐18.36        \<.001           \<.001          \<.001    14.39   0.43   13.57‐15.27   13.62   0.49   12.68‐14.62   13.03   0.35   12.35‐13.73
  Overall work Impairment %[b](#ijcp12900-note-0007){ref-type="fn"}   19.98   0.39                19.23‐20.75     \<.001           \<.001          \<.001    16.78   0.49   15.84‐17.78   15.49   0.55   14.44‐16.62   14.90   0.40   14.14‐15.69
  Activity impairment %                                               27.54   0.32                26.93‐28.17     \<.001           \<.001          \<.001    24.09   0.42   23.28‐24.93   21.72   0.48   20.79‐22.68   21.28   0.34   20.61‐21.96
  EU5                                                                                                                                                                                                                                 
  Absenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}               6.15    0.22                5.72‐6.6        .194             .087            \<.001    5.59    0.36   4.93‐6.34     5.33    0.40   4.6‐6.17      4.47    0.26   3.99‐5.01
  Presenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}              18.47   0.28                17.93‐19.02     \<.001           \<.001          \<.001    16.24   0.43   15.42‐17.11   14.65   0.46   13.77‐15.57   14.98   0.36   14.3‐15.7
  Overall work Impairment %[b](#ijcp12900-note-0007){ref-type="fn"}   22.08   0.32                21.46‐22.72     0.001            \<0.001         \<.001    20.06   0.52   19.07‐21.1    18.33   0.56   17.27‐19.45   18.09   0.42   17.28‐18.93
  Activity impairment %                                               26.29   0.26                25.78‐26.81     .004             \<.001          \<.001    24.83   0.43   24.01‐25.68   22.94   0.47   22.04‐23.88   21.82   0.34   21.16‐22.49
  China                                                                                                                                                                                                                               
  Absenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}               8.63    0.28                8.1‐9.21        \<.001           \<.001          \<.001    6.74    0.40   6‐7.56        5.60    0.49   4.72‐6.66     4.46    0.38   3.78‐5.26
  Presenteeism %[b](#ijcp12900-note-0007){ref-type="fn"}              28.55   0.44                27.7‐29.42      .016             \<.001          \<.001    26.45   0.73   25.06‐27.93   22.95   0.94   21.18‐24.87   22.04   0.87   20.39‐23.83
  Overall work impairment %[b](#ijcp12900-note-0007){ref-type="fn"}   32.52   0.49                31.57‐33.49     0.029            \<0.001         \<0.001   30.39   0.82   28.81‐32.05   26.25   1.06   24.26‐28.41   24.54   0.95   22.76‐26.47
  Activity impairment %                                               28.68   0.41                27.89‐29.5      .006             \<.001          \<.001    26.46   0.68   25.16‐27.82   23.69   0.89   22.01‐25.5    23.49   0.85   21.88‐25.21

SE, standard error; CI, confidence interval. ^a^Covariates included: age, ethnicity (for US only), education, BMI category, and CCI. ^b^Asked only of the employed population. For US: Have not quit (N=6319), 0‐4 years (N=2780), 5‐10 years (N=1837) and 11+ years (N=3675). For EU5: Have not quit (N=9262), 0‐4 years (N=3016), 5‐10 years (N=2148), and 11+ years (N=3883). For China: Have not quit (N=3616), 0‐4 years (N=1132), 5‐10 years (N=508) and 11+ years (N=559).
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4. Discussion {#ijcp12900-sec-0021}
=============

Smoking is associated with significant societal and individual consequences across a variety of health and economic outcomes.[1](#ijcp12900-bib-0001){ref-type="ref"}, [2](#ijcp12900-bib-0002){ref-type="ref"} Importantly, the results of the current study suggest that quitting smoking serves to reduce the burden to workplace productivity and activity impairment. This is most exemplified by recent quitters, between 0 and 4 years postcessation, having significantly lower impact on absenteeism, presenteeism and activity impairment compared with current smokers. Additionally, this burden was so reduced that former smokers appeared mostly indistinguishable from never smokers. These findings suggest that in addition to the health and economic benefits experienced by employees who quit, employers themselves benefit economically from tobacco cessation in the workplace by the increase in work productivity experienced by their employers.

This study provides important simultaneous documentation of the work‐related burden of smoking in the US, EU5 and China using large‐scale representative survey sampling methodology. While there was some variation among regions, after controlling for demographic and health characteristics, comparisons revealed that overall, employees who smoked reported significant impairments across multiple domains of work productivity as well as activity impairment compared with former and never smokers. These results are consistent with previous work establishing the detrimental impact of smoking and tobacco use on work‐related outcomes in the US and EU.[2](#ijcp12900-bib-0002){ref-type="ref"}, [26](#ijcp12900-bib-0026){ref-type="ref"}

Interestingly, those who are trying to quit had greater impairment than current smokers and former smokers, suggesting that the act of quitting can be a challenging process and previous research has shown that smokers can benefit from support during the quitting process.[27](#ijcp12900-bib-0027){ref-type="ref"} This suggests a role for employers in providing support to employees currently in the process of quitting smoking to enhance the chance of successful quitting given the rapid benefits that were identified. The overall pattern of results across all regions thus suggests that former smokers and never smokers have the lowest impairment compared with other groups.

Quitting smoking has been shown not only to reverse many of the detrimental health effects of tobacco use over time but also to reduce impairments in work productivity in a cost‐effective manner. Of note in this study, former smokers were statistically indistinguishable from never smokers in some work productivity outcomes across a number of regions sampled, although this result warrants further replication and investigation. This may suggest that in a period of 4 years or less, the burden of smoking is lessened to such a degree that former smokers begin to appear similar to those who have never smoked in terms of work productivity loss and activity impairment. This timeline is contrasted with some medical and health‐related benefits from quitting smoking, which may take substantially longer (eg, 10‐20 years) for maximum risk reduction.[28](#ijcp12900-bib-0028){ref-type="ref"}, [29](#ijcp12900-bib-0029){ref-type="ref"}, [30](#ijcp12900-bib-0030){ref-type="ref"}

To the authors\' knowledge, no previous findings examining the impact of quitting on work productivity and impairment across both time and geographic region simultaneously exist. The novel findings of this study support the need for increased investment in employer‐based smoking cessation programs irrespective of geography as well as identifying system wide approaches to help smokers during the quit process. This provides further evidence that employers should seek to implement and promote tobacco cessation programs in the workplace, as well as to provide ongoing support for their employees who are seeking to quit or have successfully quit.

4.1. Strengths and limitations {#ijcp12900-sec-0022}
------------------------------

This study possesses a number of strengths, including its methodological approach and ability to provide unique insight into the impact of quitting on work‐related outcomes. Similar large‐scale representative survey methodology was utilised in order to gain information from individuals across three global regions, providing exclusive insight into the impact of smoking on work‐related outcomes among a diverse population of tobacco users. Importantly, this methodological approach enabled two study objectives to be examined, the impact of smoking behaviour on workplace productivity and the improvement over time provided by cessation. Although the results presented provide insight into the potential consequences of smoking in the workplace, it is important to consider them in the context of study limitations. The results of this study were based on self‐reported data and thus smoking status was not independently verified. Additionally, the percentage of smokers in China was lower than identified in China by other sources, potentially indicating a healthier population. Further, the cross‐sectional nature of this survey precludes causal inferences from being drawn regarding the primary study variables.

More specifically, we cannot infer whether smoking makes people less productive or whether more productive people are less likely to smoke. While we controlled for some potentially confounding variables, it is still possible that not all confounders were captured. There may be other variables, such as mental illness, related to smoking and work productivity that were not controlled for in this study. As those with mental illness are both more likely to smoke and exhibit decreased employee productivity,[31](#ijcp12900-bib-0031){ref-type="ref"}, [32](#ijcp12900-bib-0032){ref-type="ref"} quitting smoking may not alleviate the work productivity burden within the mentally ill population. Future research could examine how smoking affects work productivity loss in the mentally ill population.

4.2. Conclusions {#ijcp12900-sec-0023}
----------------

Smoking is associated with important health and economic consequences for individuals and society at large. This study provides important insight into burden exerted by smoking on work productivity in the US, EU5 and China. Among former smokers, improved work productivity outcomes were evident even among those who had quit relatively recently. This finding further reinforces the immediate benefits that can emerge for both individuals and employers. These novel findings provide further support for the widespread implementation of workplace smoking cessation programs.
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